{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T02:09:47Z","timestamp":1773281387017,"version":"3.50.1"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100011151","name":"American Academy of Ophthalmology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011151","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","award":["2,3"],"award-info":[{"award-number":["2,3"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Ocular Surface"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.jtos.2022.08.006","type":"journal-article","created":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T14:01:48Z","timestamp":1660744908000},"page":"342-344","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["The genus decision: Potential impact on ophthalmic pharmaceuticals"],"prefix":"10.1016","volume":"26","author":[{"given":"Gary D.","family":"Novack","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristin D.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jtos.2022.08.006_bib1","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/clpt.2008.297","article-title":"Ophthalmic drug delivery: development and regulatory considerations","volume":"85","author":"Novack","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jtos.2022.08.006_bib2","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S1542-0124(11)70010-6","article-title":"Pipeline: the development of drugs vs. devices","volume":"9","author":"Novack","year":"2011","journal-title":"Ocul Surf"},{"issue":"4","key":"10.1016\/j.jtos.2022.08.006_bib3","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.jtos.2020.08.003","article-title":"FDA review times for new drugs in ophthalmology","volume":"18","author":"Carpenter","year":"2020","journal-title":"Ocul Surf"},{"issue":"12","key":"10.1016\/j.jtos.2022.08.006_bib4","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1016\/j.ophtha.2021.05.023","article-title":"Ab-externo MicroShunt versus trabeculectomy in primary open-angle glaucoma: one-year results from a 2-year randomized, multicenter study","volume":"128","author":"Baker","year":"2021","journal-title":"Ophthalmol."},{"key":"10.1016\/j.jtos.2022.08.006_bib5","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.2147\/OPTH.S362932","article-title":"Canaloplasty and trabeculotomy combined with phacoemulsification for glaucoma: 12-month results of the GEMINI study","volume":"16","author":"Gallardo","year":"2022","journal-title":"Clin Ophthalmol"},{"issue":"6590","key":"10.1016\/j.jtos.2022.08.006_bib6","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1126\/science.abq4276","article-title":"How a site peddles author slots in reputable publishers' journals","volume":"376","author":"Chawla","year":"2022","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.jtos.2022.08.006_bib7","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.clinthera.2022.02.005","article-title":"Pledging to address scientific Bias in published literature","volume":"44","author":"Maron","year":"2022","journal-title":"Clin Therapeut"},{"issue":"3","key":"10.1016\/j.jtos.2022.08.006_bib8","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.clinthera.2021.11.019","article-title":"Industry sponsor influence in clinical trial reporting in Canada: a qualitative interview study","volume":"44","author":"Morrow","year":"2022","journal-title":"Clin Therapeut"},{"issue":"3","key":"10.1016\/j.jtos.2022.08.006_bib9","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.clinthera.2022.02.001","article-title":"Reporting of clinical trial results: aligning incentives and requirements to do the right thing","volume":"44","author":"Zarin","year":"2022","journal-title":"Clin Therapeut"},{"key":"10.1016\/j.jtos.2022.08.006_bib10","article-title":"FDA rejects two proposed cancer drugs developed in China","author":"Loftus","year":"2022","journal-title":"Wall St J"}],"container-title":["The Ocular Surface"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542012422000787?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542012422000787?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T04:50:43Z","timestamp":1761540643000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542012422000787"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":10,"alternative-id":["S1542012422000787"],"URL":"https:\/\/doi.org\/10.1016\/j.jtos.2022.08.006","relation":{},"ISSN":["1542-0124"],"issn-type":[{"value":"1542-0124","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The genus decision: Potential impact on ophthalmic pharmaceuticals","name":"articletitle","label":"Article Title"},{"value":"The Ocular Surface","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtos.2022.08.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}